.jpeg)
Which company produces tucatinib?
Tucatinib (tucatinib) is an anti-cancer drug used to treat HER2-positive breast cancer. It is a small molecule inhibitor of HER2. Tucatinib was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly known as Oncothyreon, which later became part of Seattle Genetics). In 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval of tucatinib in combination with trastuzumab for the treatment of RAS wild-type HER2-positive unresectable or metastatic colorectal cancer. Common side effects of tucatinib include diarrhea, palmar-plantar paresthesia, nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia and rash, which may cause harm to the developing fetus or infant.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
